徐绍鹏,万征

• 1:天津医科大学总医院心脏内科

摘要(Abstract)：

<正>与裸金属支架相比,药物洗脱支架(DES)可降低再狭窄发生率,改善经皮冠状动脉介入治疗(PCI)患者的预后。然而研究显示,第一代DES[西罗莫司洗脱支架(Cypher)和紫杉醇洗脱支架(Taxus Express)]增加晚期血栓形成和内皮化不良风险,提高了病死率[1-2]。2008年逐渐上市的新一代支架因为采用了与第一代支架不同的支架框架,新的抗增生药物和多聚物涂层,被称为第二代DES[2-3],其生物相容性更

关键词(KeyWords)： 冠状动脉;药物洗脱支架;预后

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 徐绍鹏,万征

参考文献(References)：

• [1]Camenzind E,Steg PG,Wijns W.Stent thrombosis late after implantation of first-generation drug-eluting stents:a cause for concern.Circulation,2007,115:1440-1455.
• [2]Lange RA,Hillis LD.Second-generation drug-eluting coronary stents.N Engl J Med,2010,362:1728-1730.
• [3]Doostzadeh J,Clark LN,Bezenek S,et al.Recent progress in percutaneous coronary intervention:evolution of the drug-eluting stents,focus on the XIENCE V drug-eluting stent.Coron Artery Dis,2010,21:46-56.
• [4]Akin I,Schneider H,Ince H,et al.Second-and thirdgeneration drug-eluting coronary stents:progress and safety.Herz,2011,36:190-196.
• [5]Serruys PW,Silber S,Garg S,et al.Comparison of zotarolimuseluting and everolimus-eluting coronary stents.N Engl J Med,2010,363:136-146.
• [6]Taniwaki M,Stefanini GG,Silber S,et al.4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents:a report from the RESOLUTE All-Comers trial(A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).J Am Coll Cardiol,2014,63:1617-1625.
• [7]de la Torre Hernández JM,Alfonso F,Gimeno F,et al.Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2(Estudio Espanol Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2).JACC Cardiovasc Interv,2010,3:911-919.
• [8]Herrador JA,Fernandez JC,Guzman M,et al.Comparison of zotarolimus-versus everolimus-eluting stents in the treatment of coronary bifurcation lesions.Catheter Cardiovasc Interv,2011,78:1086-1092.
• [9]Shammas NW,Shammas GA,Nader E,et al.Outcomes of patients treated with the everolimus-eluting stent versus the zotarolimus eluting stent in a consecutive cohort of patients at a tertiary medical center.Vasc Health Risk Manag,2012,8:205-211.
• [10]Tada T,Byrne RA,Cassese S,et al.Comparative efficacy of 2zotarolimus-eluting stent generations:resolute versus endeavor stents in patients with coronary artery disease.Am Heart J,2013,165:80-86.
• [11]von Birgelen C,Basalus MW,Tandjung K,et al.A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients:the TWENTE trial.J Am Coll Cardiol,2012,59:1350-1361.
• [12]Sen H,Lam MK,Tandjung K,et al.Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting xience V stents in the randomized TWENTE trial:Comparison of 2-year clinical outcome.Catheter Cardiovasc Interv,2015,85:74-81.
• [13]Tandjung K,Basalus MW,Sen H,et al.Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience V stents:insights from the genderstratified,randomized,controlled TWENTE trial.Catheter Cardiovasc Interv,2013,82:396-405.
• [14]Lee JM,Youn TJ,Park JJ,et al.Comparison of 9-month angiographic outcomes of Resolutezotarolimus-eluting and everolimus-eluting stents in a real world setting of coronary intervention in Korea.BMC Cardiovasc Disord,2013,13:65.
• [15]Park KW,Lee JM,Kang SH,et al.Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice:patientrelated and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries.J Am Coll Cardiol,2013,61:536-544.
• [16]Park KW,Lee JM,Kang SH,et al.Everolimus-eluting xience v/promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.JACC Cardiovasc Interv,2014,7:471-481.
• [17]Lee JM,Park KW,Han JK,et al.Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in realworld practice(from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).Am J Cardiol,2014,114:1329-1338.
• [18]Park KW,Kang SH,Kang HJ,et al.A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention:HOST-ASSURE(harmonizing optimal strategy for treatment of coronary artery stenosis-safety&effectiveness of drug-eluting stents&anti-platelet regimen),a randomized,controlled,noninferiority trial.J Am Coll Cardiol,2014,63:2805-2816.
• [19]Hannan EL,Zhong Y,Wu C,et al.Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions:two-year outcomes in New York State.Catheter Cardiovasc Interv,2013,81:1097-1105.
• [20]von Birgelen C,Sen H,Lam MK,et al.Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention(DUTCH PEERS):a randomised,single-blind,multicentre,noninferiority trial.Lancet,2014,383:413-423.
• [21]Cho SC,Jeong MH,Kim W,et al.Clinical outcomes of everolimus-and zotarolimus-eluting stents in patients with acute myocardial infarction for small coronary artery disease.J Cardiol,2014,63:409-417.
• [22]Mehilli J,Richardt G,Valgimigli M,et al.Zotarolimus-versus everolimus-eluting stents for unprotected left main coronary artery disease.J Am Coll Cardiol,2013,62:2075-2082.
• [23]Kim JS,Kim BK,Jang IK,et al.Comparis On of neointimalco Veragebetw EenzotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography(COVER OCT).Am Heart J,2012,163:601-607.
• [24]Kim S,Kim JS,Shin DH,et al.Comparison of early strut coverage between zotarolimus-and everolimus-eluting stents using optical coherence tomography.Am J Cardiol,2013,111:1-5.
• [25]Song HG,Kang SJ,Ahn JM,et al.Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-,everolimus-,and sirolimus-eluting stent implantation.Catheter Cardiovasc Interv,2014,83:873-878.
• [26]Smits PC,Hofma S,Togni M,et al.Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimuseluting stent(COMPARE II):a randomised,controlled,noninferiority trial.Lancet,2013,381:651-660.
• [27]Brugaletta S,Gomez-Lara J,Diletti R,et al.Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds:insights from the ABSORB and SPIRIT trials.Catheter Cardiovasc Interv,2012,79:219-228.
• [28]Costopoulos C,Latib A,Naganuma T,et al.Comparison of early clinical outcomes between absorbbioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.Catheter Cardiovasc Interv,2015,85:E10-15.